Icelanders, whose unusually low genetic variability makes them ideal for
studies on the origin of diseases, have agreed to reveal the secrets of their
genes to pharmaceuticals company Hoffmann-La Roche. The deal, worth $200
million, gives the company and its partner—deCode Genetics of
Reykjavik—exclusive rights to develop drugs from the genetic data of
Iceland’s population. In return, Icelanders will receive any resulting medicines
free.
More from 91av
Explore the latest news, articles and features
Popular articles
Trending 91av articles
1
Monkeys walk around a virtual world using only their thoughts
2
A whole new way to prevent death from sepsis shows promise
3
How autoimmune conditions can unexpectedly drive mental illness
4
Can we ‘vaccinate’ ourselves against stress?
5
Why the right kind of stress is crucial for your health and happiness
6
Collapse of key ocean current may release billions of tonnes of carbon
7
We might finally know how to use quantum computers to boost AI
8
People are refusing transfusions from donors vaccinated against covid
9
How to spot the Lyrid meteor shower tonight
10
Exclusive report: Inside Chernobyl, 40 years after nuclear disaster
